abstract |
There is provided an isolated polypeptide, derivative, isoform and/or fragment thereof, wherein the polypeptide is a mutant of a Group 5 allergen. There are also provided pharmaceutical composition(s) and vaccine(s) for the treatment of subjects allergic to at least one Group 5 allergen. |